CCXI
Churchill Capital Corp XI
OpenVolumeMkt capP/EEPSDiv yield
Day – 52-wk –
Expected move
InputsNext report
Last report
—
Largest filed tie
0
filed ties
13F top-10 QoQ
Top fund weight
—
Churchill Capital Corp XI
Expected move
InputsNext report
Last report
—
Largest filed tie
0
filed ties
13F top-10 QoQ
Top fund weight
—
News
No changes.
No changes.
Same SIC code · 6
Same SEC industry code: Nordson Corp, Regal Rexnord Corp, Esab Corp and 3 more; no measured co-movers for Churchill Capital Corp XI.
Same SIC code · 6
Same SEC industry code: Nordson Corp, Regal Rexnord Corp, Esab Corp and 3 more; no measured co-movers for Churchill Capital Corp XI.
Annual filing, covered
10-K parsed · Mar 26 '26
Supply-chain ties, covered
None disclosed
Fund holders, covered
No N-PORT holders
13F holdings, covered
13F quarter · Jun 30 '26
Management, not covered
Not covered · DEF 14A, 8-K 5.02
Company IR feed, not covered
News via newswires & EDGAR
Products, patents, hiring, not covered
Not covered
Annual filing, covered
10-K parsed · Mar 26 '26
Supply-chain ties, covered
None disclosed
Fund holders, covered
No N-PORT holders
13F holdings, covered
13F quarter · Jun 30 '26
Management, not covered
Not covered · DEF 14A, 8-K 5.02
Company IR feed, not covered
News via newswires & EDGAR
Products, patents, hiring, not covered
Not covered
No thesis.
ChemoCentryx, Inc., a biopharmaceutical company, focuses on the development and commercialization of new medications for inflammatory disorders, autoimmune diseases, and cancer in the United States. It offers TAVNEOS (avacopan), an orally administered selective C5aR inhibitor for the treatment of adult patients with severe active anti-neutrophil cytoplasmic autoantibody-associated vasculitis. The company also develops TAVNEOS for the treatment of patients with severe hidradenitis suppurativa, as well as patients with complement 3 glomerulopathy, and lupus nephritis. In addition, it develops CCX559, an orally administered inhibitor for programmed death protein 1/programmed death-ligand 1 for the treatment of various cancers; and CCX507, an orally administered inhibitor of the chemokine receptor known as CCR9, which has completed Phase I clinical trial for the treatment of inflammatory bowel disease. Further, the company has early-stage drug candidates that targets Th17 driven diseases and CCR6. ChemoCentryx, Inc. was incorporated in 1996 and is headquartered in San Carlos, California.
ChemoCentryx, Inc., a biopharmaceutical company, focuses on the development and commercialization of new medications for inflammatory disorders, autoimmune diseases, and cancer in the United States. It offers TAVNEOS (avacopan), an orally administered selective C5aR inhibitor for the treatment of adult patients with severe active anti-neutrophil cytoplasmic autoantibody-associated vasculitis. The company also develops TAVNEOS for the treatment of patients with severe hidradenitis suppurativa, as well as patients with complement 3 glomerulopathy, and lupus nephritis. In addition, it develops CCX559, an orally administered inhibitor for programmed death protein 1/programmed death-ligand 1 for the treatment of various cancers; and CCX507, an orally administered inhibitor of the chemokine receptor known as CCR9, which has completed Phase I clinical trial for the treatment of inflammatory bowel disease. Further, the company has early-stage drug candidates that targets Th17 driven diseases and CCR6. ChemoCentryx, Inc. was incorporated in 1996 and is headquartered in San Carlos, California.
ChemoCentryx, Inc.
11.25
+0.56 · +5.23%
post 11.52 +2.40%
Expected move
No implied move.
| Manager | Value | % base | |
|---|---|---|---|
| Empyrean Capital Partners | $55.0M | 11.08% | new |
| BlueCrest | $41.3M | 8.33% | new |
| Fort Baker | $35.0M | 7.05% | −20.48% |
| Polar Asset Management Partners | $34.9M | 7.04% | 0.00% |
| Magnetar Financial | $33.5M | 6.75% | −28.94% |
| Manager | Value | % base | |
|---|---|---|---|
| Empyrean Capital Partners | $55.0M | 11.08% | new |
| BlueCrest | $41.3M | 8.33% | new |
| Fort Baker | $35.0M | 7.05% | −20.48% |
| Polar Asset Management Partners | $34.9M | 7.04% | 0.00% |
| Magnetar Financial | $33.5M | 6.75% | −28.94% |